Yazen at European Congress on Obesity (ECO) 2025: Pioneering Modern Obesity Treatment through Digital Innovation

In May 2025, the picturesque city of Malaga hosted the European Congress on Obesity (ECO 2025), organised by the European Association for the Study of Obesity (EASO). Recognised worldwide for its comprehensive scientific programme and expert-led sessions, ECO provides a vital platform for the latest advancements in obesity prevention, treatment, and management. Yazen was one of key abstracts presented, demonstrating how digital health solutions and personalised care are transforming obesity treatment and improving long-term patient outcomes.

Yazen’s Participation and Contributions at ECO 2025

Yazen was proud to participate in the 32nd European Congress on Obesity, held from 10 to 14 May 2025 in Malaga. As a leader in healthcare innovation, Yazen contributed with groundbreaking research and innovative solutions with 3 abstracts, presented both orally to hundreds of participants and by posters. Our approach, aligned with the EASO Framework for Obesity Diagnosis, Staging, and Management, emphasizes moving beyond traditional BMI metrics to consider individual health factors and body composition.

Our dedicated team engaged in meaningful discussions with clinicians, researchers, and industry leaders from across Europe and beyond, exchanging ideas on the latest trends and future directions in obesity prevention, treatment, and long-term management. Central to our approach is a commitment to addressing the stigma surrounding obesity through people-first language and empathetic patient care.

The biggest highlight was our Chief Medical Officer, Dr Martin Carlsson, successfully presenting Yazen's latest outstanding clinical outcome orally, with our key abstract, showing data on over 2,000 patients, showing significant weight loss alongside improvements in lipid profiles, reductions in fat mass, and other key metabolic markers, validating the efficacy and holistic nature of the Yazen Model, our digital care programme. His presentation showcased the real-world outcomes of our digital obesity management programme, demonstrating how integrated digital support combined with a holistic pharmacological treatment delivers sustainable weight loss and improves metabolic health, despite lower dosage of medications to minimize side-effects. Read and download the full abstract here.

In addition to the key abstract, two posters were also showcased during ECO 2025:

• The first, by main author Dr. Elin Skoglund, titled “Modern Obesity Treatment Delivered via a Digital Platform,” detailed how the Yazen Model combines medical treatment, lifestyle modifications, and social support to achieve durable results. A key aspect of this model includes behavioral elements that promote self-reflection, address potential biases, and foster improved communication between patients and healthcare providers.
• The second, featuring the main author MD, PhD. David Buchebner, titled “High Adherence to GLP-1 Receptor Agonists Over 18 Months”, explored medication adherence within our digital weight management programme and its positive impact on long-term success.

The ECO 2025 congress provided vital opportunities for networking, knowledge sharing, and forming collaborations to shape the future of obesity management worldwide.

‍Revolutionising Obesity Management: The Yazen Model

Yazen has been at the forefront of transforming obesity care by combining personalised healthcare with digital tools that has today already successfully treated over 40,000 patients in Sweden, Netherlands, Spain, Germany, Norway, UK and Denmark, soon to be expanded to more markets. Our Yazen Model integrates medication, tailored lifestyle interventions, and ongoing behavioural support through advanced digital platforms.

The results are compelling — an average weight loss of 16.6% over 18 months, achieved even with lower doses of medication, demonstrating both the safety and efficacy of our approach. Results supported by insights from the SURMOUNT-5 trial, with results also presented at ECO 2025, highlighting that lower doses of GLP-1 receptor agonists can be equally effective, with fewer side effects and better adherence. This directly underpins the Yazen model’s emphasis on personalised, dose-optimised treatment plans, maximising benefits while minimising adverse effects, with the patient and society first in mind.

Real-world data like this, reinforces the importance of flexible, patient-specific dosing strategies — key pillars of the Yazen Model.

Emerging Trends and Future Directions in Obesity Care

ECO 2025 also highlighted several healthcare trends aligning with Yazen’s approach:

• ‍Holistic, patient-centred care, including psychological, nutritional, and behavioural support as integral elements of effective obesity management.‍
• Early prevention and intervention, especially in childhood obesity*, to address long-term health risks and reduce the incidence of metabolic diseases in adulthood.‍
• The significance of flexible, patient-specific dosing: The SURMOUNT-5 study reinforced that lower doses of GLP-1 receptor agonists can be just as effective in eliciting weight loss, with fewer side effects and better adherence, supporting the Yazens approach of personalised, dose-optimised treatment plans, where an average weight loss of 16.6% over 18 months was achieved even with most patients receiving doses of around 1 mg semaglutide, to minimize side effects, demonstrating both the safety and effectiveness of the Yazen Model.‍
• Broadening the perspective on obesity metrics: There is a clear shift from relying solely on BMI as the primary health indicator towards more precise and predictive measures such as waist-to-height ratio. These metrics better predict cardiometabolic risk and align with the core principles of personalised, effective obesity management.‍
• The potential of digital health and telemedicine: These tools have enormous capacity to improve access, adherence, and real-time support, making sustainable obesity care scalable and more accessible for diverse populations.

Yazen’s Ongoing Commitment

As ECO 2025 drew to a close, the consensus was clear: personalised, sustainable and more digital obesity treatments are the future of healthcare. Yazen remains committed to leading this evolution by continuously refining our digital platform, integrating the latest research, and expanding access to evidence-based obesity solutions.

Our consistent, validated outcomes — demonstrated through numerous abstracts and posters as well as 40,000 successfully treated patients and more constantly joining to get help — affirm that innovation at the intersection of technology and healthcare can unlock new possibilities for effective, long-lasting obesity management.

We are dedicated to advancing personalised treatment strategies that adapt to individual needs, ensuring better adherence, fewer side effects, and ultimately, improved health outcomes — all for the patients best.

For further information or to download/read the Yazen abstracts presented at ECO 2025 in full, please visit here.‍

References:

• Yazen Health LinkedIn Updates
• SURMOUNT-5 Trial Results: Aronne et al. 2025. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. NEJM. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2416394 
• About ECO 2025: https://eco2025.org/ 

*At the moment Yazen does not treat childhood obesity.